The antidiabetic drug metformin decreases mitochondrial respiration and tricarboxylic acid cycle activity in cultured primary rat astrocytes
- 19 March 2017
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 95 (11) , 2307-2320
Abstract
Metformin is an antidiabetic drug that is used daily by millions of patients worldwide. Metformin is able to cross the blood‐brain barrier and has recently been shown to increase glucose consumption and lactate release in cultured astrocytes. However, potential effects of metformin on mitochondrial tricarboxylic acid (TCA) cycle metabolism in astrocytes are unknown. We investigated this by mapping 13C labeling in TCA cycle intermediates and corresponding amino acids after incubation of primary rat astrocytes with [U‐13C]glucose. The presence of metformin did not compromise the viability of cultured astrocytes during 4 hr of incubation, but almost doubled cellular glucose consumption and lactate release. Compared with control cells, the presence of metformin dramatically lowered the molecular 13C carbon labeling (MCL) of the cellular TCA cycle intermediates citrate, α‐ketoglutarate, succinate, fumarate, and malate, as well as the MCL of the TCA cycle intermediate‐derived amino acids glutamate, glutamine, and aspartate. In addition to the total molecular 13C labeling, analysis of the individual isotopomers of TCA cycle intermediates confirmed a severe decline in labeling and a significant lowering in TCA cycling ratio in metformin‐treated astrocytes. Finally, the oxygen consumption of mitochondria isolated from metformin‐treated astrocytes was drastically reduced in the presence of complex I substrates, but not of complex II substrates. These data demonstrate that exposure to metformin strongly impairs complex I–mediated mitochondrial respiration in astrocytes, which is likely to cause the observed decrease in labeling of mitochondrial TCA cycle intermediates and the stimulation of glycolytic lactate production.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Ho 5204/2-1)
This publication has 84 references indexed in Scilit:
- Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitusBMC Pharmacology and Toxicology, 2013
- The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosisBMC Pharmacology and Toxicology, 2013
- Two Weeks of Metformin Treatment Enhances Mitochondrial Respiration in Skeletal Muscle of AMPK Kinase Dead but Not Wild Type MicePLOS ONE, 2013
- Novel Model of Neuronal Bioenergetics: Postsynaptic Utilization of Glucose but not Lactate Correlates Positively with Ca 2+ Signalling in Cultured Mouse Glutamatergic NeuronsASN Neuro, 2012
- Reductive carboxylation supports growth in tumour cells with defective mitochondriaNature, 2011
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)PLOS ONE, 2011
- Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple SclerosisThe Journal of Immunology, 2009
- The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathwayProceedings of the National Academy of Sciences, 2009
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001